Significant Insider buy of Concert Pharmaceuticals (CNCE) Shares Breaks neutral Trend of Last Quarter

Monday, October 23, 2017 10:15 PM ET

Significant Insider buy of Concert Pharmaceuticals (CNCE) Shares Breaks neutral Trend of Last Quarter

There was a substantial insider purchase in Concert Pharmaceuticals shares today as disclosed in a filing with the SEC. One insider — Partners L P/Il Bvf, 10% Owner — bought 331,916 shares in the company having a net market value of approximately $5,256,720. This is the first insider buy/sell trade in the past 90 days.

The level of buy-sell trading at Concert Pharmaceuticals is near the 183 member peer company average. The Biotechnology & Medical Research peer group saw 225 buy/sell trades during this period for an average of 1.2 transactions per company. However, the number of shares per buy/sell trade transacted by Concert Pharmaceuticals insiders is higher. Within the peer group there were 9,358,376 shares purchased and 51,304,587 shares sold with company insiders disposing of 186,428 shares on average.

The data obtained in composing and writing in this story eliminates all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers.

Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.

For more information, contact UpTick at info@uptickdata.com. Copyright 2017 UpTick Data Technologies. All rights reserved.

This entry was posted in InsiderNews and tagged , , , , . Bookmark the permalink.